We transform Australia & New Zealand's most promising medical discoveries into the latest medical therapies that save lives & improve quality of life, while generating returns for investors.

The MRCF is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, the Australian and New Zealand governments, Australian state governments and over 50 leading medical research institutes and research hospitals.

Learn more about who we are

Portfolio

We’re immensely proud of our portfolio. Partnering with talented scientists, clinicians and entrepreneurs, we have supported more than 40 companies to date.
The collaborative nature of the MRCF provides a supportive investment process, fostering best practice commercialisation and encouraging innovation. The MRCF works closely with its 50+ Member Institutes to identify promising opportunities with strong commercialisation potential.
The MRCF is unique, in that it is structured as a collaboration between the investors and the Member Institutes, with experienced representatives from each institute providing a ‘peer review’ assessment of opportunities through representation on the Investment Review Committee (IRC).
The MRCF works closely with the Member Institutes to identify promising opportunities, ‘working them up’, completing due diligence and establishing the start-up company. Most importantly, the MRCF guides the early stage investments through the development process to a trade-sale, partnering, next round financing or into stand-alone, growing businesses.

Aravax
Aravax

Creating the first safe and rapidly effective treatment for peanut allergy

View Project
Amaroq Therapeutics
Amaroq Therapeutics

Targeting long non-coding RNAs for next generation cancer therapies

View Project
Okogen
Okogen

Developing therapeutics for the treatment of ophthalmic diseases, including adenoviral conjunctivitis

View Project
Ena Respiratory
Ena Respiratory

Developing therapies for respiratory infections in patients with asthma and COPD

View Project
EBR Systems
EBR Systems

Developing therapies for patients with cardiac rhythm diseases and heart failure using wireless cardiac stimulation

View Project
PolyActiva
PolyActiva

A clinical-stage biotechnology company focussed on the development of ocular implants

View Project
Certa Therapeutics
Certa Therapeutics

Developing novel anti-fibrotic therapies for the treatment of scarring associated with chronic kidney disease

View Project
Azura Ophthalmics
Azura Ophthalmics

Developing a novel therapy for the treatment of Meibomian Gland Dysfunction

View Project
See all

Members

Our member institutes span every state and territory in Australia. Here is a snapshot.

Institute
Auckland Cancer Society Research Centre

Since its inception in 1956, the Auckland Cancer Society Research Centre (ACSRC) has published nearly 1,000 papers in international scientific and medical journals, and filed more than 100 patent applications for new anti-cancer drugs.

View
Institute
The Burnet Institute

The Burnet Institute is an independent, not‐for‐profit Australian organization that is unique in its approach of linking medical research with public health action to address many of the major health problems affecting disadvantaged communities. This approach allows us to develop innovative health solutions ranging from the highly technological through to those that are community-based.

View
Institute
Centre for Biomedical Technologies

Better lives through advanced medical technologies.

View

Got an idea?

The MRCF collaboration is innovation in action: We provide a path for taking medical science from conception into the real world.

Our Venture capital model is unique. We don’t simply provide investment, we entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.

Learn more